RU2322985C2 - Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости - Google Patents

Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости Download PDF

Info

Publication number
RU2322985C2
RU2322985C2 RU2003127718/15A RU2003127718A RU2322985C2 RU 2322985 C2 RU2322985 C2 RU 2322985C2 RU 2003127718/15 A RU2003127718/15 A RU 2003127718/15A RU 2003127718 A RU2003127718 A RU 2003127718A RU 2322985 C2 RU2322985 C2 RU 2322985C2
Authority
RU
Russia
Prior art keywords
flumazenil
cocaine
drug
treatment
intended
Prior art date
Application number
RU2003127718/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2003127718A (ru
Inventor
ИБАНЕС Хуан Хосе ЛЕГАРДА (ES)
ИБАНЕС Хуан Хосе ЛЕГАРДА
Original Assignee
Хитиям, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хитиям, Инк. filed Critical Хитиям, Инк.
Publication of RU2003127718A publication Critical patent/RU2003127718A/ru
Application granted granted Critical
Publication of RU2322985C2 publication Critical patent/RU2322985C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
RU2003127718/15A 2001-02-15 2002-02-08 Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости RU2322985C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200100342 2001-02-15
ESP200100342 2001-02-15

Publications (2)

Publication Number Publication Date
RU2003127718A RU2003127718A (ru) 2005-01-27
RU2322985C2 true RU2322985C2 (ru) 2008-04-27

Family

ID=8496743

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003127718/15A RU2322985C2 (ru) 2001-02-15 2002-02-08 Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости

Country Status (20)

Country Link
US (2) US7186711B2 (https=)
EP (1) EP1378267B1 (https=)
JP (2) JP4272885B2 (https=)
KR (1) KR100712571B1 (https=)
CN (1) CN1327843C (https=)
AT (1) ATE363923T1 (https=)
AU (1) AU2002231811B2 (https=)
BR (1) BR0207866A (https=)
CA (1) CA2436511C (https=)
CY (1) CY1106845T1 (https=)
DE (1) DE60220512T2 (https=)
DK (1) DK1378267T3 (https=)
ES (1) ES2287255T3 (https=)
IL (1) IL157144A0 (https=)
MX (1) MXPA03007281A (https=)
NZ (1) NZ528164A (https=)
PT (1) PT1378267E (https=)
RU (1) RU2322985C2 (https=)
UA (1) UA79586C2 (https=)
WO (1) WO2002064213A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2804834C2 (ru) * 2017-07-31 2023-10-06 Новартис Аг Применение мавоглуранта при снижении употребления кокаина или при предупреждении рецидива употребления кокаина

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2436511C (en) * 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
US7855196B2 (en) 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
ES2289935B1 (es) * 2006-07-14 2008-12-16 Juan Jose Legarda Ibañez Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva.
US20110034442A1 (en) * 2007-08-08 2011-02-10 Jaun Jose Legarda Ibanez Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders
US9396280B2 (en) * 2008-06-23 2016-07-19 Microsoft Technology Licensing, Llc Command driven web site browsing
ES2702848T3 (es) 2011-02-23 2019-03-05 Coeruleus Ltd Complejos de flumazenil, composiciones que los comprenden y usos de los mismos
US9308616B2 (en) 2013-01-21 2016-04-12 Innovative Finishes LLC Refurbished component, electronic device including the same, and method of refurbishing a component of an electronic device
WO2015054730A1 (en) * 2013-10-14 2015-04-23 Palmaya Pty Ltd Compositions and methods of administering same
CN107115359A (zh) * 2016-02-24 2017-09-01 郑恩哲 阻断海洛因或吗啡毒品中毒路径的点滴处方及其应用
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013297A1 (en) * 1992-12-11 1994-06-23 Smithkline Beecham Plc . Potassium channel activators and use thereof in therapy
RU2095062C1 (ru) * 1991-03-22 1997-11-10 Каби Фармациа АБ Блокатор синдрома отмены, являющегося результатом привыкания к чрезмерному потреблению лекарств или веществ, вызывающих привыкание, фармакологическая композиция на его основе и способ облегчения или предотвращения синдрома отмены

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
GB9420010D0 (en) 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
CA2436511C (en) 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
US6740677B2 (en) 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2095062C1 (ru) * 1991-03-22 1997-11-10 Каби Фармациа АБ Блокатор синдрома отмены, являющегося результатом привыкания к чрезмерному потреблению лекарств или веществ, вызывающих привыкание, фармакологическая композиция на его основе и способ облегчения или предотвращения синдрома отмены
WO1994013297A1 (en) * 1992-12-11 1994-06-23 Smithkline Beecham Plc . Potassium channel activators and use thereof in therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
РЕГИСТР ЛЕКАРСТВЕННЫХ СРЕДСТВ РОССИИ. Энциклопедия лекарств. - M.: РЛС, 2000, с.988-989, реферат Entrez PubMed: Klotz U. et al. Pharmaco-kinetics and clinical use of flumazenil (Ro 15-1788). Clin Pharmacokinet. 1988 Jan; 14 (1): l-12. Review. [on line] PMID: 3127102 [найдено 19.12.2005]. реферат Entrez PubMed: Derlet R.W. et al. Anticonvulsant modification of cocaineinduced toxicity in the rat. Neuropharmacology. 1990 Mar; 29 (3): 255-9. [on line] PMID: 2325832 [найдено 09.02.2006]. *
реферат Entrez PubMed: Uki F. et al. [The effect of flumazenil administration on acute cocaine intoxication of rats] Arukoru Kenkyuto Yakubutsu Ison. 1994 Apr; 29 (2): 92-102 [on line] PMID: 8192615 [найдено 09.02.2006]. Руководство по медицине «THE MERCK MANUAL». - M.: Мир, 1997, т.2, с.23. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2804834C2 (ru) * 2017-07-31 2023-10-06 Новартис Аг Применение мавоглуранта при снижении употребления кокаина или при предупреждении рецидива употребления кокаина

Also Published As

Publication number Publication date
KR100712571B1 (ko) 2007-05-02
HK1061817A1 (en) 2004-10-08
EP1378267B1 (en) 2007-06-06
PT1378267E (pt) 2007-09-11
NZ528164A (en) 2006-03-31
ATE363923T1 (de) 2007-06-15
US20070142364A1 (en) 2007-06-21
DE60220512T2 (de) 2008-02-07
WO2002064213A1 (es) 2002-08-22
DK1378267T3 (da) 2007-10-08
JP2008201799A (ja) 2008-09-04
MXPA03007281A (es) 2005-01-25
DE60220512D1 (de) 2007-07-19
JP4272885B2 (ja) 2009-06-03
AU2002231811B2 (en) 2006-02-16
KR20040010592A (ko) 2004-01-31
CN1491125A (zh) 2004-04-21
CA2436511A1 (en) 2002-08-22
US20060122219A1 (en) 2006-06-08
IL157144A0 (en) 2004-02-08
RU2003127718A (ru) 2005-01-27
US7186711B2 (en) 2007-03-06
EP1378267A1 (en) 2004-01-07
BR0207866A (pt) 2004-03-23
CN1327843C (zh) 2007-07-25
JP2004521904A (ja) 2004-07-22
CY1106845T1 (el) 2012-05-23
UA79586C2 (en) 2007-07-10
ES2287255T3 (es) 2007-12-16
CA2436511C (en) 2009-08-04

Similar Documents

Publication Publication Date Title
US20080132492A1 (en) Use of Flumazenil in the Production of a Drug for the Treatment of Alcohol Dependency
JP2008201799A (ja) コカイン依存症治療用薬剤
US20200113882A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
JP2004519461A5 (https=)
JP2004521904A5 (https=)
US4552865A (en) Psychotropic drugs
KR20080004615A (ko) 알코올 및/또는 흥분성 물질 남용의 치료를 위한 선택적클로라이드 채널 조절제의 용도
RU2134106C1 (ru) Способ нормализации толерантности организма к веществу
JPH04159224A (ja) ヒトの糖尿病性知覚障害および末梢神経障害の治療剤
AU2006200922A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
HK1061817B (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
HK1061661B (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
UA59481C2 (uk) Спосіб лікування абстинентного синдрому у хворих з опійною залежністю
HK1173911B (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with multiple sclerosis

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140209